Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…
The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…
China has the greatest burden of hepatitis C virus (HCV) in the world. Chronically infected HCV patients are at a high risk of developing cirrhosis, liver cancer, and early death if left untreated…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…